Legend Biotech (LEGN) Work In Process (2022 - 2023)

Legend Biotech (LEGN) posted quarterly Work In Process of $2.3 million for Q3 2023, up 6.72% on a QoQ basis from $2.1 million in Q2 2023.

Legend Biotech (LEGN) Work In Process (2022 - 2023) Analysis & Trends

Legend Biotech (LEGN) has reported Work In Process for 2 consecutive years, with $2.3 million the latest figure, recorded in Q3 2023.

Quarterly Work In Process changed N/A year-over-year to $2.3 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $2.3 million (changed N/A YoY) and the FY2022 annual result came in at $690000.0, changed N/A from the prior year.
Work In Process rose to $2.3 million in Q3 2023 per LEGN's latest filing, from $2.1 million in the prior quarter.
Over the last five years, Work In Process for LEGN reached as high as $2.3 million in Q3 2023 and fell as low as $690000.0 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Legend Biotech	8.69 Bn	7.79 Bn	129.70 Mn

Download Data